Want to see AU:PTX full AI Analyst Report?
PTX Stock Chart & Stats
AU$0.09
>-AU$0.01(-8.70%)
At close: 4:00 PM EDT
AU$0.09
>-AU$0.01(-8.70%)
Day’s Range― - ―
52-Week RangeAU$0.04 - AU$0.13
Previous CloseN/A
Volume3.39M
Average Volume (3M)690.15K
Market Cap
AU$89.38M
Enterprise ValueAU$59.08M
Total Cash (Recent Filing)AU$9.77M
Total Debt (Recent Filing)AU$495.89K
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding1,051,514,500
10 Day Avg. Volume838,009
30 Day Avg. Volume690,151
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)3.11
Price to Sales (P/S)8.13
P/FCF Ratio-4.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth (~44% YoY)Sustained ~44% year-over-year revenue growth signals meaningful commercial or developmental traction for a clinical-stage biotech. Over 2-6 months this trend supports increased partner interest, validates programs, and improves bargaining power for licensing or collaboration deals that fund further development.
Conservative Balance Sheet / Low LeverageVery low debt reduces refinancing and interest-rate risk for a cash-consuming biotech. This conservative capital structure preserves financial flexibility, limits fixed financing costs, and increases optionality to pursue partnerships or time capital raises more favorably over the next several months.
Partnering/Licensing-Focused Revenue ModelA business model centered on licensing and collaborations is appropriate for a clinical-stage firm: it provides a durable path to monetize assets without building commercial infrastructure, can supply non-dilutive or milestone-driven funding, and aligns incentives with larger pharma partners.
Bears Say
Persistent Structural LossesOngoing operating and net losses indicate the company has not reached profitability and will likely rely on external financing. Over a 2-6 month horizon this increases dilution and execution risk, as continued R&D spend must be funded while revenue growth has yet to offset operating costs.
Consistent Negative Operating & Free Cash FlowNegative operating and free cash flow every year, with worsening FCF, creates a structural cash-burn profile. This shortens runway absent fundraising or milestone payments, elevates the likelihood of frequent capital raises, and increases dependency on partners or markets to finance development.
Declining Equity / Negative Returns On EquityDeclining equity and persistently negative ROE reflect capital erosion from losses and potential dilution. Over months this reduces internal funding capacity, weakens balance-sheet resilience, and limits strategic flexibility when negotiating partnerships or coping with unexpected development setbacks.
Prescient Therapeutics Limited News
PTX FAQ
What was Prescient Therapeutics Limited’s price range in the past 12 months?
Prescient Therapeutics Limited lowest share price was AU$0.04 and its highest was AU$0.13 in the past 12 months.
What is Prescient Therapeutics Limited’s market cap?
Prescient Therapeutics Limited’s market cap is AU$89.38M.
When is Prescient Therapeutics Limited’s upcoming earnings report date?
Prescient Therapeutics Limited’s upcoming earnings report date is Aug 20, 2026 which is in 11 days.
How were Prescient Therapeutics Limited’s earnings last quarter?
Prescient Therapeutics Limited released its earnings results on Feb 24, 2026. The company reported -AU$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.004.
Is Prescient Therapeutics Limited overvalued?
According to Wall Street analysts Prescient Therapeutics Limited’s price is currently Overvalued.
Does Prescient Therapeutics Limited pay dividends?
Prescient Therapeutics Limited does not currently pay dividends.
What is Prescient Therapeutics Limited’s EPS estimate?
Prescient Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Prescient Therapeutics Limited have?
Prescient Therapeutics Limited has 1,051,514,500 shares outstanding.
What happened to Prescient Therapeutics Limited’s price movement after its last earnings report?
Prescient Therapeutics Limited reported an EPS of -AU$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.353%.
Which hedge fund is a major shareholder of Prescient Therapeutics Limited?
Currently, no hedge funds are holding shares in AU:PTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prescient Therapeutics Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.54%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
11.46%
Trailing 12-Months
Company Description
Prescient Therapeutics Limited
Prescient Therapeutics Limited (PTX.AX) is an Australian clinical-stage oncology firm dedicated to creating novel therapeutic agents for various cancer types. The company's primary experimental compound, PTX-200, is currently undergoing several clinical trials: Phase 2a for HER2-negative breast cancer, Phase 1B/2 for acute myeloid leukemia that has relapsed or is resistant to treatment, and Phase 1b for ovarian cancer that is recurrent, persistent, or resistant to platinum-based therapies. Additionally, PTX-100, a RhoA inhibitor, is being developed to target both blood cancers and solid tumors, specifically those characterized by Ras and RhoA genetic mutations. Prescient Therapeutics has also forged a strategic alliance with The University of Texas MD Anderson Cancer Center to advance the development of a blood cancer binder for their OmniCAR platform. Founded in Melbourne, Australia, in 1986, the company operated as Virax Holdings Limited until its rebranding as Prescient Therapeutics Limited in December 2014.
Technical Analysis
Imugene
―
Immutep Ltd
―
Telix Pharmaceuticals
―
Clarity Pharmaceuticals Ltd.
―
Radiopharm Theranostics Limited
―